PrEP monitoring schedule SEO Brief & AI Prompts

The laboratory monitoring schedule for PrEP is baseline HIV testing with a 4th‑generation antigen/antibody assay (and HIV RNA if recent high‑risk exposure or symptoms), baseline renal function including serum creatinine with eGFR or creatinine clearance, hepatitis B surface antigen and immunity testing, pregnancy testing where applicable, and baseline STI screening, followed by HIV and STI testing every 3 months and creatinine at 3 months then every 6 months if stable. This schedule aligns with CDC guidance for quarterly HIV screening and commonly used thresholds for renal safety (eGFR or creatinine clearance ≥60 mL/min for tenofovir disoproxil fumarate), and reflects standard STI screening frequency for sexually active at‑risk populations with counseling.

Mechanistically, monitoring prevents HIV seroconversion on PrEP going unrecognized and detects drug‑related toxicity. National frameworks such as CDC, WHO and BHIVA recommend a combination of laboratory tools: 4th‑generation antigen/antibody assays and HIV RNA PCR for early infection, nucleic acid amplification tests (NAAT) for rectal/pharyngeal STI screening, and renal assessment using CKD‑EPI eGFR or Cockcroft‑Gault creatinine clearance equations. Incorporating PrEP lab tests that include hepatitis B serology and pregnancy testing ensures safety, continuity of care, and documentation in the medical record. The PrEP monitoring frequency balances sensitivity for incident infection and adverse effects against feasibility in primary care and sexual health settings. Laboratory cadence should be adapted to local prevalence, renal risk factors, and patient adherence patterns.

Key nuances influence interpretation and action. A common and dangerous mistake is starting PrEP without documenting a baseline 4th‑generation assay and, when recent exposure is possible, an HIV RNA — a negative antigen/antibody alone can miss acute infection. Another frequent error is relying on serum creatinine without calculating eGFR or creatinine clearance; tenofovir disoproxil fumarate is generally avoided if creatinine clearance is below 60 mL/min, whereas tenofovir alafenamide may be used at lower thresholds but requires consult of product labeling. Hepatitis B screening PrEP omissions create risk for HBV flare if therapy is stopped; positive HBsAg requires linkage to hepatology or vaccination planning if susceptible. Clinicians should document PrEP monitoring frequency and contingency plans for abnormal results.

Practical steps include recording baseline 4th‑generation HIV and, when indicated, HIV RNA; baseline serum creatinine with eGFR or Cockcroft‑Gault calculation; HBsAg and HBsAb; urine or serum pregnancy test where relevant; and site‑specific NAAT for gonorrhea and chlamydia. Schedule repeat HIV and STI screening every 3 months, repeat creatinine at 3 months then every 6 months if eGFR remains stable, and escalate to confirmatory HIV RNA and specialist referral for any reactive tests or eGFR decline, and ensure test results are clearly communicated. This page presents a structured, step‑by‑step framework for monitoring PrEP and managing abnormal laboratory results.